Takeda Overview
Takeda is a global pharmaceutical company based in Japan. The company conducts research and development, manufacturing, and marketing of pharmaceutical products in various therapeutic areas, including oncology, gastroenterology, and central nervous system disorders. Takeda is also involved in the production of vaccines and has a significant presence in the global pharmaceutical market. Takeda Pharmaceutical Company has a presence in Israel, mainly through its subsidiary Takeda Israel Ltd. The company conducts research and development activities in the country, focusing on areas such as oncology, neuroscience, and rare diseases. Takeda Israel also works with local partners and academic institutions to advance research and development in these areas. Additionally, Takeda Israel is involved in the commercialization and distribution of Takeda's products in Israel.
Latest News
growth-positive
Strauss Group (TASE:STRS): Assessing Valuation After Mixed Q2 Earnings and Sales Growth
Strauss Group has released its second quarter and half-year earnings, showing a rise in sales for both periods in 2025. Despite the increase in revenue, net income has decreased, indicating potential cost pressures or margin changes. The companys stock has risen by nearly 64% over the past year, though recent gains have slowed. Strauss Groups price-to-earnings ratio is slightly below the Asian Food industry average, suggesting it is valued in line with sector peers. The companys strong profit growth and above-average profit margin support its current valuation. However, potential risks include slowing net income growth or changes in consumer demand.
growth-positive
Westin Desaru Coast Resort partners with CAYIN Technology for digital signage
CAYIN Technology has partnered with Westin Desaru Coast Resort in Johor, Malaysia, to enhance guest communication and operational efficiency through the implementation of its CMS-WS server and CAYIN Signage Player. This collaboration involves the use of digital signage to provide real-time updates across 14 Samsung displays in various areas of the resort. The project was executed in partnership with Hola Media, which provided integration services, including installation, design, staff training, and support. The system has improved communication, reduced staff workload, and enhanced the guest experience, preparing the resort for future digital expansion.
Partners
growth-positive
Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025
Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) announced the launch of a next-generation submerged ammonia pump at the Gastech Conference. This pump is designed to be the safest and most reliable in the industry, addressing common maintenance issues with its seal-less, maintenance-friendly, copper-free construction. The pump can deliver over 2,500m3 per hour and has a mean time between outages of over 16,000 hours. This launch is part of Nikkiso CE&IGs ongoing innovation in ammonia handling, with the company having decades of experience in this field. The pump is expected to meet growing demand for ammonia in various sectors, including power generation and shipping.
Product Stage
growth-positive
Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma | MarketScreener
Y-mAbs Therapeutics, Inc. and Takeda Israel have announced that the Israeli Ministry of Health has approved DANYELZA for the treatment of pediatric patients and adult patients with relapsed or refractory high-risk neuroblastoma. DANYELZA will be commercialized by Takeda Israel under an exclusive license and distribution agreement. This approval marks Y-mAbs first marketing authorization outside of the U.S. and demonstrates their commitment to expanding the reach of their commercial stage products internationally. The approval is seen as a milestone for the collaboration between Y-mAbs and Takeda and is expected to benefit pediatric patients with unmet medical needs. DANYELZA was developed by researchers at Memorial Sloan Kettering Cancer Center and is exclusively licensed by Y-mAbs.
Customers
Takeda Israel Awarded the Best Place to Work in Israel for 2018
Team Members
4
Employees: 51-200
Web & Social Links
| Website | www.takeda.com |
Locations
Ef'al Street 25, Petah Tikva, Israel
2 Chome Nihonbashihoncho, Chuo City, Tokyo 103-0023, Japan
Photos & Videos
No files yet
Takeda Business
Business models
—
Product stage
—
Employees
51-200
Sector
—Target Customer
—Core Technology
—Tags (6)
neurosciencepharmaceuticalsgastroenterologyoncologyrare-diseasesinnovation-centerTakeda Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Takeda Lifecycle
Takeda News
6 articles
growth-positive
Strauss Group (TASE:STRS): Assessing Valuation After Mixed Q2 Earnings and Sales Growth
Strauss Group has released its second quarter and half-year earnings, showing a rise in sales for both periods in 2025. Despite the increase in revenue, net income has decreased, indicating potential cost pressures or margin changes. The companys stock has risen by nearly 64% over the past year, though recent gains have slowed. Strauss Groups price-to-earnings ratio is slightly below the Asian Food industry average, suggesting it is valued in line with sector peers. The companys strong profit growth and above-average profit margin support its current valuation. However, potential risks include slowing net income growth or changes in consumer demand.
growth-positive
Westin Desaru Coast Resort partners with CAYIN Technology for digital signage
CAYIN Technology has partnered with Westin Desaru Coast Resort in Johor, Malaysia, to enhance guest communication and operational efficiency through the implementation of its CMS-WS server and CAYIN Signage Player. This collaboration involves the use of digital signage to provide real-time updates across 14 Samsung displays in various areas of the resort. The project was executed in partnership with Hola Media, which provided integration services, including installation, design, staff training, and support. The system has improved communication, reduced staff workload, and enhanced the guest experience, preparing the resort for future digital expansion.
Partners
growth-positive
Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025
Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) announced the launch of a next-generation submerged ammonia pump at the Gastech Conference. This pump is designed to be the safest and most reliable in the industry, addressing common maintenance issues with its seal-less, maintenance-friendly, copper-free construction. The pump can deliver over 2,500m3 per hour and has a mean time between outages of over 16,000 hours. This launch is part of Nikkiso CE&IGs ongoing innovation in ammonia handling, with the company having decades of experience in this field. The pump is expected to meet growing demand for ammonia in various sectors, including power generation and shipping.
Product Stage
growth-positive
Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma | MarketScreener
Y-mAbs Therapeutics, Inc. and Takeda Israel have announced that the Israeli Ministry of Health has approved DANYELZA for the treatment of pediatric patients and adult patients with relapsed or refractory high-risk neuroblastoma. DANYELZA will be commercialized by Takeda Israel under an exclusive license and distribution agreement. This approval marks Y-mAbs first marketing authorization outside of the U.S. and demonstrates their commitment to expanding the reach of their commercial stage products internationally. The approval is seen as a milestone for the collaboration between Y-mAbs and Takeda and is expected to benefit pediatric patients with unmet medical needs. DANYELZA was developed by researchers at Memorial Sloan Kettering Cancer Center and is exclusively licensed by Y-mAbs.
Customers
Takeda Israel Awarded the Best Place to Work in Israel for 2018
growth-positive
https://www.jpost.com/Business-and-Innovation/Japan-based-Takeda-readies-strategic-investment-in-Israel-402859
Takeda Pharmaceuticals, the largest pharmaceutical company in Asia, is increasing efforts for strategic investments in Israel through its venture fund. The company is looking to fund promising seed companies that fit in with its strategic vision. Takeda launched a commercial subsidiary in Israel in 2013 and helped establish a biotech accelerator called FutuRx in 2014. Takeda is now doing diligence on several promising prospects for investment. The expansion in Israel is part of the companys strategy to engage more globally and tap into innovation outside of its traditional markets. Takeda sees the future in greater personalization of medicine and is attending the IATI Biomed conference in Israel to explore opportunities.
InvestmentPartners
Takeda Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 72 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Takeda Internal
Recent Updates
vichian suksoir
· vichian9703@gmail.com · Automatic · 2023-04-04 08:20:02.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-04 18:49:30.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-24 19:49:03.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-11 19:48:21.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:49:05.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-10-14 10:08:08.000000
Matan Eblagon
· matane@sncentral.org · Automatic · 2023-03-21 17:22:29.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-22 13:09:35.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-11 19:48:21.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2023-01-24 19:52:44.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-24 19:42:52.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-04 18:49:15.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-04 18:49:15.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:01:30.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-10-14 10:08:08.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-04 18:49:15.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-22 06:36:19.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-24 19:42:52.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:55:38.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-04 18:49:15.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-04 18:49:15.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-04 18:49:15.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-04 18:49:30.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:21:32.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2025-02-06 12:26:57.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-24 19:49:03.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-04 18:48:49.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-08-31 12:40:52.000000
Yanina Wainscheinker
· yanina.wain@gmail.com · Manual · 2019-04-05 18:20:13.000000
Yanina Wainscheinker
· yanina.wain@gmail.com · Manual · 2019-04-05 18:20:13.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 66/100 |
| Missing | product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed |
| BI Verification | Vered Waxman |
| Crunchbase | takeda-pharmaceutical |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Maor Perlov |
| Updater email | maor.perlov@sncentral.org |
| Last update | 2023-01-24T00:00:00.000Z |
| Created | 2019-04-05T00:00:00.000Z |
| Status detail | Public on TYO on Dec, 2013;Public on NYSE on Dec, 2018; |